Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E.
Target Price
The average target price of SRPT is 21 and suggests 22% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell